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Interactions between the host and gut microbial community likely contribute to Crohn disease (CD) pathogenesis; however,
direct evidence for these interactions at the onset of disease is lacking. Here, we characterized the global pattern of ileal gene
expression and the ileal microbial community in 359 treatment-naive pediatric patients with CD, patients with ulcerative
colitis (UC), and control individuals. We identified core gene expression profiles and microbial communities in the affected
CD ilea that are preserved in the unaffected ilea of patients with colon-only CD but not present in those with UC or control
individuals; therefore, this signature is specific to CD and independent of clinical inflammation. An abnormal increase of
antimicrobial dual oxidase (DUOX2) expression was detected in association with an expansion of Proteobacteria in both
UC and CD, while expression of lipoprotein APOA1 gene was downregulated and associated with CD-specific alterations
in Firmicutes. The increased DUOX2 and decreased APOA1 gene expression signature favored oxidative stress and Th1
polarization and was maximally altered in patients with more severe mucosal injury. A regression model that included APOA1
gene expression and microbial abundance more accurately predicted month 6 steroid-free remission than a model using
clinical factors alone. These CD-specific host and microbe profiles identify the ileum as the primary inductive site for all forms
of CD and may direct prognostic and therapeutic approaches.

Introduction

Current evidence suggests that the inflammatory bowel diseases
(IBDs) Crohn disease (CD) and ulcerative colitis (UC) are caused
by a complex interaction among host genetic background, microbial shifts, and environmental cues, leading to inappropriate
chronic activation of the mucosal immune system (1–3). While
it is difficult to establish causality in patient-based studies, it is
reasonable to suggest that large inception cohorts that include
clinical, genetic, mucosal, and microbial profiling might be the
optimal way to address the diversity associated with IBD pathogenesis with adequate power. A recent meta-analysis of IBD genetic studies identified 163 IBD risk loci (4), and many of these
risk alleles exhibit infection-related balancing natural selection
Conflict of interest: The authors have declared that no conflict of interest exists.
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Reference information: J Clin Invest. 2014;124(8):3617–3633. doi:10.1172/JCI75436.

(4). Consistent with this finding, an overall dysfunction in the human gut microbial community has been described in both longstanding adult-onset IBD (5) and treatment-naive pediatric-onset
IBD (6), and patients exhibit altered responses to bacterial DNA
(7). Animal models have conclusively shown causality in the requirement for bacterial colonization in the development of intestinal inflammation in genetically susceptible hosts (3). However,
characterization of host/microbial profiles in the affected and
unaffected mucosa at the onset of disease in large patient-based
cohorts has been lacking.
Diagnostic and therapeutic decisions in IBD are based primarily on clinical and endoscopic severity and histopathologic
analysis of intestinal biopsies. With this approach, only a minority of patients experience durable remission, which may be
due to substantial heterogeneity in the underlying pathogenic
mechanisms not accounted for by current classification systems
(8). The two main forms of IBD, CD and UC, share many genetic
jci.org   Volume 124   Number 8   August 2014
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Table 1. RISK RNA-seq cohort clinical and demographic characteristics

Mean (SD) age (yr)
Male gender (%)
MED ethnicity (3 of 4
grandparents) (%)
Perianal involvement (%)
Ileal deep ulcers (%)
BMI z-score < –2 (%)
PCDAI at diagnosis
≤10 (inactive, %)
11–30 (mild, %)
>30
(moderate to severe, %)

Ctl
(n = 43)

UC1
(n = 45)

cCD1
(n = 37)

UC2
(n = 28)

cCD2
(n = 26)

iCD1
(n = 90)

iCD2
(n = 90)

All iCD
(n = 180)

iCD-DU
(n = 78)

iCD-noDU
(n = 102)

11 (3)
65
97

12 (3)
47
87

12 (4)
54
91

13 (4)
71
86

13 (3)
54
77

12 (3)
63
90

12 (3)
60
88

12 (3)
62
89

12 (3)
58
91

12 (3)
65
88

0
0
3

0
0
2

16
0
22

0
0
4

24
0
15

19
44
28

17
42
16

18
43
22

19
100
23

17
0
21

NA
NA
NA

NA
NA
NA

8
36
56

NA
NA
NA

4
38
58

8
37
55

10
44
46

9
41
50

12
32
56

7
48A
46

Differences between selected groups were tested by ANOVA for continuous variables and χ2 for dichotomous variables. MED, mixed European descent.
A
P = 0.0421 vs. iCD-DU.

susceptibility loci but differ in anatomical location and disease
behavior, often dictating different medical and surgical approaches, further implying the need for additional classification
approaches. More importantly, disease classification should take
into account potential response to current and future therapy.
This is especially relevant now, when second-line biologic medications are on track for approval (9, 10) by the FDA, and there is
an ongoing need to identify patients that will derive the greatest
relative benefit from early biological therapy with anti–TNF-α
agents (8, 11). A recent comparative effectiveness study that used
the same inception cohort as the current report showed that early
anti–TNF-α therapy is superior to other approaches in achieving
1-year steroid- and surgery-free remission (SSFR) (11). No clinical or demographic parameters were specifically associated with
therapeutic response, suggesting that additional information is
needed to better define patient subsets. The use of gene expression or microbial markers to support diagnosis and adjust therapy for specific subsets of IBD is currently limited. In one single-center study, researchers tested for association between ileal
or colonic gene expression and subsequent clinical and mucosal
response to anti–TNF-α therapy in adults with established CD
(12). Overall, 12 of 19 patients experienced healing of colonic ulcers with anti–TNF-α, and baseline expression of specific colonic
genes was associated with subsequent response. Remarkably,
only 1 of 18 patients experienced healing of ileal ulcers with anti–
TNF-α, and hence no gene pattern was defined for this response.
Therefore, there is a pressing clinical need to define pathogenic
mechanisms driving ileal ulcers and to test whether genomic and
microbial data will improve patient classification.
Patient-based and murine studies have suggested that the
terminal ileum, which contains approximately 50% of the Peyer’s
patches in the gut, plays a central role as a sensor of bacterial colonization and tolerance and is likely the primary inductive site for
mucosal immunologic pathogenesis in CD (13–15). We therefore
focused on capturing the net output of contributing environmental and genetic factors by performing high-throughput ileal microbial community and host gene expression analyses from DNA
and RNA extracted from ileal biopsies collected at the time of
3618
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patients’ initial diagnostic endoscopy (Figure 1A). Previous studies have been limited by small sample size, variable biopsy locations, long duration of disease, and multiple prior treatments (12,
16–19). We addressed these limitations by analyzing ileal biopsies
obtained at the time of diagnosis in a large treatment-naive prospective inception cohort of patients with early-onset (pediatric)
IBD, known as the RISK cohort. We have recently used the RISK
cohort to define (6) a mucosal microbial axis in treatment-naive
CD, which includes an increased abundance of Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae and
decreased abundance of Erysipelotrichales, Bacteroidales, and
Clostridiales. This microbial axis correlated strongly with clinical
disease severity within CD. Additionally, we found that antibiotics, sporadically prescribed in response to the initial symptoms,
amplified the microbial dysbiosis (6). Here, we further expand
our understanding, at the ileal mucosal level, by specifically characterizing the host gene expression and the associated microbial
abundance in a broader spectrum of disease phenotypes. To capture a CD-specific signature, independent of the confounding effects of local mucosal inflammation, we defined the global pattern
of gene expression and microbial community in both clinically
affected (ileal CD [iCD]) and unaffected (colon-only CD [cCD])
ilea, in comparison with noninvolved ilea in UC and non-IBD controls (Ctl). We aimed to thereby identify both core CD pathogenic
host/microbe associations and to test for association among these
host-transcriptomic and microbial factors, disease severity, and
subsequent clinical course (Figure 1A).

Results

Identification of a core iCD gene expression signature. The Crohn’s
and Colitis Foundation of America–sponsored RISK study is a prospective inception cohort study, which enrolled 1,276 pediatric patients with IBD at diagnosis at 28 sites in North America between
2008 and 2012 (Supplemental Figure 1 and Supplemental Excel
file 1; supplemental material available online with this article;
doi:10.1172/JCI75436DS1). All patients were treatment naive, with
ileal biopsies obtained during the initial diagnostic colonoscopy.
Only subjects with a confirmed diagnosis of CD, UC, or non-IBD
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Figure 1. APOA1 and DUOX2 gene coexpression signatures define pathogenic ileal modules. (A) Study
groups included Ctl, UC, cCD, and iCD. Ileal 16S DNA sequencing and mRNA sequencing were used to
define microbial profiles and gene expression signatures, respectively. (B) Venn diagram shows 1,281
genes (core iCD signature) that were differentially expressed (fold change ≥ 1.5) between 2 independent
iCD and Ctl groups. (C) Heat maps of average gene expression for the clinical subgroups for DUOX2 or
APOA1 gene coexpression signatures (Pearson correlation 0.98<|r|<1). Venn diagram indicates DUOX2
and APOA1 gene coexpression signature overlap. Selected upregulated (red) and downregulated (blue)
genes are listed, with the graphs showing the average DUOX2, LCT, APOA1, and IFNG gene expression
across groups. Differences between patient subgroups were tested using Kruskal-Wallis with Dunn’s
multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Ctl. cCD-mic, cCD with abnormal
histological features; cCD N histo, cCD with normal histology.

Ctl during follow-up were included
(Table 1 and Supplemental Excel file 2).
Our initial analyses identified a core
iCD gene expression signature composed of 1,281 genes that were differentially expressed in the ilea of 2 independent iCD groups compared with
Ctl (Figure 1B, Supplemental Figure
2A, and Supplemental Excel file 3). We
conducted functional annotation enrichment analyses using several data
sources, including gene ontology to
map groups of related genes within the
core iCD gene signature to upstream
regulators, immune cell types, pathways, phenotypes, and biologic functions (Supplemental Figure 2, B and
C, and Supplemental Excel files 4–6).
These analyses provided a way to identify which known transcriptional regulators, biologic processes, and immune
cell types were likely to be upregulated
or downregulated within the ileum
based on a given gene expression pattern. Analyses were conducted using
ToppGene (20), ToppCluster (21), and
Ingenuity Pathway Analysis software.
The relative degree of upregulation or
downregulation of a given transcriptional regulator or biologic process
was provided by the activation z score
obtained as an output from Ingenuity
Pathway Analysis software (Supplemental Figure 2B), while P values for
the specific cell type, pathway, phenotype, and biologic function associated
with upregulated or downregulated
genes were obtained as an output
from ToppGene (Supplemental Excel
files 4–6). Ileal enrichment for a given
immune cell class was illustrated as
shown in Supplemental Figure 2C by
colored bars on the x axis, with the significance for each individual cell type
within the class shown as the –log10
(P value) on the y axis.
The core iCD signature was enriched for genes induced by bacterial
products and proinflammatory cytokine signaling, including the Th1 cytokine IFN-γ, whereas genes induced by
several nuclear receptors, including
HNF4α, were suppressed (Supplemental Figure 2B). Functional analyses
(20) identified enrichment of innate
antimicrobial responses and an unexpected profound loss of nuclear recep-
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Table 2. Top upregulated differentially expressed genes within
the core iCD gene signature
1
2
3
4
5

Gene

iCD1 FC

iCD2 FC

DUOXA2
MMP3
AQP9
IL8
DUOX2

34.3
21.4
21.2
18.6
15.8

51.9
29.7
32.8
27.8
19.2

Genes are listed 1–5, with that with the most differential expression being
first. FC, fold change.

tor-dependent lipid metabolic functions (Supplemental Figure 2B
and Supplemental Excel files 4 and 5). Immune cell enrichment
analysis was most significant for genes expressed by granulocytes,
myeloid dendritic cells, macrophage/monocytes, and lymphoid
stromal cells (Supplemental Figure 2C and Supplemental Excel
file 6). Within the top 5 most upregulated genes, we noted the
epithelial antimicrobial dual oxidase DUOX2 and its maturation
factor DUOXA2. Within the downregulated genes, we noted the
antiinflammatory HNF4α-dependent lipoprotein APOA1 as the
top downregulated gene (Tables 2 and 3).
The core iCD signature contains APOA1 and DUOX2 gene coexpression signatures. Strong experimental linkage to gut inflammation (22–25), together with the high fold-change expression differences, prompted us to specifically examine the pattern of APOA1
and DUOX2 gene expression in the following clinically defined
subgroups: Ctl, UC, cCD, and iCD. Patients in the cCD subgroup
met diagnostic criteria for CD but lacked visible ileal inflammation on endoscopy; patients with UC also had disease limited to
the colon. The cCD subgroup was further divided into those with
normal ileal histopathology and those with microscopic ileal inflammation. The iCD subgroup was further divided into 2 groups
based upon the presence of deep ulcers, iCD with deep ulcers
[iCD-DU], and iCD without deep ulcers [iCD-noDU]) (26). Figure
1C shows progressive increased expression of DUOX2 in the ileum
across the spectrum of Ctl, UC, cCD, and iCD, while suppression
of APOA1 expression was specific to all forms of CD. Importantly,
the 2 cCD groups showed a similar pattern of gene expression
as the 2 iCD groups; this pattern was different from UC and Ctl
(Figure 1C). We next performed Pearson correlation analysis to
define other genes within the core 1,281 iCD signature with similar patterns of gene expression as DUOX2 or APOA1 across the
predefined patient groups that therefore had high likelihood for
coregulation and shared biologic function. Pearson coexpression
correlation analysis (0.98<|r|<1) of the core iCD genes with either APOA1 or DUOX2 ileal expression identified 435 genes and
222 genes, respectively (Figure 1C, Supplemental Figures 3 and 4,
and Supplemental Excel files 7 and 8). The heat map with specific
indicated upregulated and downregulated genes further shows
the expression pattern within the 2 gene coexpression signatures
across the indicated patient groups (Figure 1C). Genes within the
DUOX2 gene coexpression signature showed increasing or decreasing signal intensity across the spectrum of patient groups
from Ctl to iCD-DU (Figure 1C), while genes within the APOA1
gene coexpression signature showed alterations that were spe3620
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cific to all forms of CD. Interestingly, the mature enterocyte digestive enzyme lactase (LCT) and members of the mucin family
(e.g., MUC4) were included in the DUOX2 gene coexpression
signature (Figure 1C and Supplemental Figures 3 and 4). By comparison, induction of the Th1 cytokine IFNG and its downstream
effector chemokine (CXCL9) was included within the CD-specific
APOA1 gene coexpression signature (Figure 1C and Supplemental
Figures 3 and 4). Importantly, genes within the 2 gene coexpression signatures showed similar expression patterns between cCD
with normal or abnormal histology and iCD-noDU and therefore
were independent of overt clinical inflammation (Figure 1C).
Immunohistochemistry confirmed the expected apical localization of DUOX2 within villous enterocytes in the CD ileum, in
conjunction with suppression of epithelial APOA1 and evidence
of increased lipid peroxidation (Figure 2A). We next performed
functional annotation enrichment analyses of the DUOX2 and
APOA1 gene coexpression signatures using Ingenuity Pathway
Analysis, ToppCluster (21), and Cytoscape (ref. 27 and Figure
2B). Functional annotation enrichment analyses for the DUOX2
gene coexpression signature essentially captured the key features of the NF-κB–dependent upregulated innate antimicrobial
response contained within the core iCD signature and reduction
of metabolic processes regulated by the glucocorticoid nuclear
receptor NR3C1 (Supplemental Excel file 9 and Supplemental
Figure 3C). Functional annotation enrichment analyses of the
APOA1 gene coexpression signature revealed decreased expression of genes regulated by HNF4α, PPARγ, and several other nuclear receptors, with associated predicted decreases in several
lipid metabolic and antioxidant functions (Supplemental Excel
file 9 and Supplemental Figure 4C). Importantly, these changes
occurred in association with upregulation of IFN-γ/STAT1dependent genes involved in Th1 polarization. Collectively,
these results defined 2 core DUOX2 and APOA1 gene coexpression signatures within the CD ileum, regulating both enterocyte
and innate and adaptive immune functions.
The APOA1 coexpression genes are enriched within a CD-specific
signature that is independent of clinical inflammation and may be
used for patient classification. Remarkably, the majority of the 1,281
genes that comprised the core iCD gene signature were also differentially expressed in the ilea of patients with cCD compared with
Ctls (1,055 of 1,281 genes, 82%) as opposed to only 18% (232 of
1,281) that were differentially expressed in the ilea of patients with
UC compared with Ctls (Supplemental Figure 5A). This included
upregulation of DUOX2 and downregulation of APOA1 in the

Table 3. Top downregulated differentially expressed genes within
the core iCD gene signature
1
2
3
4
5

Gene

iCD1 FC

iCD2 FC

APOA1
NAT8
AGXT2
CUBN
FAM151A

–10.8
–10.6
–10.2
–9.4
–9.4

–6.6
–6.8
–6.7
–6.9
–8.3

Genes are listed 1–5, with that with the least differential expression
being first.
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Figure 2. Functional annotation
enrichment analysis of the APOA1 and
DUOX2 gene coexpression signatures.
(A) Representative ileal DUOX2, APOA1,
and 4HNE immunohistochemistry
(original magnification, ×40) for Ctl
(n = 3) and iCD (n = 7). Arrows indicate
apical DUOX2 and intracellular APOA1
enterocyte staining and lamina propria
4HNE staining for lipid peroxidation.
(B) Functional annotation enrichment
analyses of the DUOX2 and APOA1
gene coexpression signatures using
ToppCluster (21) and Cytoscape (27).
Upregulated transcription factors and
biologic functions are shown as red
circles and orange boxes, respectively,
while downregulated transcription factors and biologic functions are shown as
blue circles and boxes, respectively.

cCD ileum. We then asked whether the APOA1 gene coexpression
signature would be enriched within the cCD ileum and whether
this genomic information could be used for patient classification.
Indeed, a large portion (572 of 614; 93%) of the genes from the
combined APOA1 and DUOX2 gene coexpression signatures were
also differentially expressed between cCD and Ctl (Supplemental
Excel file 10 and Supplemental Figure 5B). In contrast, only 15%
(89 of 614) of the genes from the combined APOA1 and DUOX2
gene coexpression signatures, primarily from the DUOX2 signature, were differentially expressed between UC and Ctl (Supplemental Excel file 11 and Supplemental Figure 5B). Unsupervised
hierarchical clustering analysis identified groups of biopsies with
similar ileal gene expression profiles; this analysis tested whether
the cCD ileal transcriptional profile for these 2 gene coexpression signatures would cluster with the iCD transcriptional profile,
whereas the UC transcriptional profile would cluster with the non
-IBD Ctl transcriptional profile. Results of this analysis showed

that, for the APOA1 gene coexpression signature, most cCD ileal
biopsies clustered together with iCD ileal biopsies, while most UC
ileal biopsies clustered with non-IBD Ctls (Supplemental Figure 4,
χ2 = 7.7, P = 0.005). A similar clustering was not observed when using the DUOX2 gene coexpression signature (Supplemental Figure 3, χ2 = 1.1, P = 0.3). Collectively, these data demonstrate that
altered transcriptional profiles in CD were observed even in the
histologically normal cCD ileum.
Arriving at the correct diagnosis in patients with IBD with
colon-only involvement (i.e., differentiating cCD from UC) can
be challenging with current clinical tools. Hypothesizing that diagnosis could be enhanced by genomic information, in addition
to our training cCD and UC groups (cCD1 and UC1), we used an
independent validation (cCD2 and UC2) cohort and tested classification of these groups using both unsupervised and supervised
approaches. To further refine a CD-specific signature in the ileum, we identified differentially expressed genes (179 with fold
jci.org   Volume 124   Number 8   August 2014

3621

Research article

The Journal of Clinical Investigation  

ing the model to the independent validation cohort
resulted in accurate classification of 41 of 54 patients
Clinical variables only
Clinical variables Clinical, gene expression, (76% overall accuracy). Among 17 patients classified
and gene expression and microbial variables
by the model as cCD, 15 carried a clinical diagnosis
AIC
215.293
212.706
208.089
of cCD (88% accuracy). However, among 37 patients
BIC
233.929
234.447
239.148
classified by the model as UC, only 26 carried a clinC statistics (or AUC)
0.705
0.721
0.760
ical diagnosis of UC (70% accuracy). Of the patients
0.0269
Likelihood ratio test
Clinical variables vs.
with cCD misclassified as UC, this included 4 with
clinical variables and gene
microscopic ileal histologic involvement, 6 with norexpression
0.0043
Clinical variables vs. clinical,
mal ileal histology, and 1 whose ileal histology was not
gene expression, and
recorded. This result demonstrated a reasonable level
microbial variables
of accuracy in using the ileal gene expression data
AIC, Akaike’s information criterion; BIC, Bayesian information criterion.
alone to classify the 2 colon-only forms of IBD.
We next performed functional annotation enrichment analyses for the 179 genes specifically altered in
CD independent of ileal inflammation (cCD vs. UC)
(Figure 3C). Genes from the DUOX2 gene coexpression signature
change ≥ 2 and 93 with fold change ≥ 2.5) between the cCD and
(Supplemental Excel file 12) showed decreased CYP3A4-related
UC training cohorts (cCD1 and UC1), which were also contained
NR3C1 glucocorticoid receptor signaling and an increase in NFin the DUOX2 or APOA1 gene coexpression signatures, whereby
κB–dependent innate immune activation and tissue degradation
82% (147 of 179) were from the APOA1 gene coexpression siggenes. Of particular interest, within the APOA1 gene coexpression
nature (Figure 3A and Supplemental Excel file 12). Unsupervised
signature (Supplemental Excel file 12), a marked downregulation
hierarchical clustering analysis to test for similarities in ileal gene
of several HNF4α and PPARγ nuclear receptor-dependent gluexpression between groups showed that both the training and
tathione s-transferases (GSTA1) and apolipoproteins (APOA1/4,
validation cCD cohorts clustered with iCD, irrespective of microAPOB, and APOC3) with antioxidant function and an upreguscopic inflammation, in contrast to the UC training and validation
lation of an IFN-γ/STAT1-dependent Th1 signature was again
cohorts, which clustered with Ctl (Figure 3B and Supplemental
noted. Collectively these results define a core iCD gene coexpresFigure 5C, χ2 = 11.8, P = 0.0006 for training cohort).
sion signature and associated biologic functions that were largely
Supervised classification algorithms may be used to develop
independent of overt clinical inflammation (Figure 3C).
models to classify unknown patient groups (in this case to classify
Upstream regulators and biologic functions associated with mucCD vs. UC) based upon gene expression data that differ within a
cosal ulceration. Endoscopic severity in CD is defined by the prestraining set of known patient groups. The Support Vector Machine
ence of deep ulcers (Figure 4A), and FDA approval of new theralgorithm is a machine learning approach, which is commonly
apies requires evidence of mucosal healing (8, 29). However, the
used to classify 2 patient classes based upon differential expreshost expression signature and microbial composition associated
sion of biologic data and, in fact, was used recently to distinguish
with the pathogenesis of this critical clinical parameter has not
cCD from UC with 77% accuracy by cross-validation in a model
been defined in a large cohort of treatment-naive patients. We
based upon differential colon protein abundance (28). We thereidentified 345 differentially expressed genes associated with deep
fore conducted a supervised classification analysis using the cCD1
ulcers within the core iCD signature (Figure 4A, Supplemental
gene list versus UC1 gene list for the cCD1/UC1 training cohort to
Figure 6, and Supplemental Excel file 13). Analysis performed usdevelop a classification model using the Support Vector Machine
ing Ingenuity Pathway Analysis software identified enrichment of
algorithm in Avadis and then tested the accuracy of the model on
genes associated with increased bacterial products and proinflamthe independent validation cohort (26 cCD2 and 28 UC2). Apply-

Table 4. Characteristics of regression models to predict 6-month SSFR

Table 5. Multiple regression analysis, including clinical, gene expression, and microbial variables
Age ≥ 10 yr vs. < 10 yr
iCD-DU vs. iCD-noDU

OR

CI

0.8868
0.6244
0.0029
0.0020
0.0152

0.944
0.771
4.713
5.181
3.058

0.430, 2.075
0.271, 2.188
1.701, 13.057
1.828, 14.706
1.241, 7.576

Veillonella abundant

0.5183

1.634

0.368, 7.25

Veillonella
nonabundant

0.0028

0.231

0.089,0.604

PCDAI > 30
PCDAI ≤ 30

Anti-TNF therapy
APOA1 expression level > 80th
percentile
Blautia abundant (>70th percentile)
vs. nonabundant

3622
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Figure 3. The ileal APOA1 gene coexpression signature is specific to all forms of CD. (A) The
Venn diagram shows the overlap of 179 genes differentially expressed 2-fold between patients
with cCD and UC and genes within the DUOX2 and APOA1 coexpression modules. (B) A heat
map of 93 of the above-mentioned 179 genes after averaging and hierarchical clustering of
gene expression, with a fold change of 2.5 between the cCD and UC training cohorts for the
indicated clinical subgroups. The training cohort included 17 cCD with abnormal histological
features, 17 cCD with normal histology, and 45 UC. The independent validation cohort included
14 cCD with abnormal histological features, 11 cCD with normal histology, and 28 UC. The
blue arrow indicates APOA1, and the red arrow indicates DUOX2. (C) The results of functional
annotation enrichment analyses (IPA, Ingenuity Systems) using the DUOX2 and APOA1 gene
coexpression signatures. Upregulated transcription factors and target genes are shown in
orange and red, respectively, while downregulated transcription factors and target genes are
shown in blue and green, respectively. Biologic functions associated with these groups of
genes are also shown.
jci.org   Volume 124   Number 8   August 2014
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Figure 4. Gene expression signature and biologic pathways associated with mucosal ulceration. (A) Image of ileal deep ulcers and Venn diagram
showing 345 genes from the core iCD gene signature, which overlap with differentially expressed genes (Audic Claverie method with Benjamini-Hochberg
FDR correction [0.05], fold change ≥ 1.5), between iCD-DU and iCD-noDU. A heat map of averaged gene expression and that after hierarchical clustering
for the iCD-DU gene list for the indicated clinical subgroups. Specific upregulated (red) and downregulated (blue) genes are listed. (B) IPA functional
annotation enrichment analyses to detect upstream regulators and biologic functions associated with the mucosal ulceration (iCD-DU) gene expression
signature are shown. The activation z score for biologic function enrichment (P value range: 6E-8 to 3E-26) and upstream regulator enrichment (P value
range: 3E-10 to 1E-56) depicts the degree of activation or suppression of a given regulator or function. (C) Immune cell–type enrichment of upregulated
genes for iCD-DU (238 of 345 genes) and upregulated genes for iCD-noDU (524 of 936 genes) was determined using the Immunological Genome Project
data series as a reference through ToppGene (20). Ileal enrichment for a given immune cell class (e.g., granulocytes [GN]) is illustrated by colored bars on
the x axis, with the significance for each individual cell subtype within the class shown as the –log10 (P value) on the y axis. pDC, plasmacytoid DC; MF,
macrophages; MO, monocytes.

matory cytokine signaling, reduced nuclear receptor signaling,
and a broad range of immune responses, including myeloid cell
and lymphocyte activation (Figure 4B). Several biologic functions,
including reactive oxygen species and hydrogen peroxide production, angiogenesis, and connective tissue degradation, were
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notably enriched within the iCD-DU gene coexpression signature
(Figure 4B). We tested for immune cell–type enrichment between
iCD-DU and iCD-noDU by conducting functional annotation enrichment analyses of immune cell–type gene expression using the
Immunological Genome Project data series as a reference through
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ToppGene (20). Ileal enrichment for a given immune cell class
(e.g., granulocytes) is illustrated in Figure 4C by colored bars on
the x axis, with the significance for each individual cell subtype
within the class shown as the –log10(P value) on the y axis. The
most significant signal within iCD-DU was for granulocytes, followed by myeloid dendritic cells and B cells, while iCD-noDU
showed a different order of enrichment, with high representations
of myeloid dendritic cells, macrophages, and lymphoid stromal
cells, in the absence of the pronounced granulocyte signal (Figure
4C). These data define biologic pathways and associated immune
cell types specifically associated with severe mucosal ulceration.
A fundamental clinical problem, as well as a difficulty in trial
design in CD, is the lack of correlation between clinical disease
activity indices and the severity of mucosal injury as defined by
deep ulcers (8, 29). Consistent with this observation, stratifying
the 180 patients with iCD by the pediatric Crohn’s disease activity index (PCDAI) identified only 43 differentially expressed
genes within the core iCD signature between those with mild
symptoms (PCDAI ≤ 30) and those with moderate-severe symptoms (PCDAI > 30) at diagnosis. Therefore, there was no clear
association between the modest number of ileal genes associated with more severe symptoms and the much more robust
gene coexpression signature associated with tissue ulceration
(Supplemental Excel files 13 and 14).
Shifts in the ileal microbial community are preserved in the unaffected CD ileum. Murine studies have established a definitive requirement for bacterial colonization in the development of mucosal inflammation in the genetically susceptible host (30, 31).
Functional annotation enrichment analyses of the core iCD gene
signature demonstrated enrichment of genes associated with
myeloid cell responses (Supplemental Excel file 6, P < 1.60E-44
to 6.74E-69), response to lipopolysaccharides (Supplemental Excel file 4, P < 1.5E-30), altered susceptibility to infection
(Supplemental Excel file 4, P < 3.1E-24), and response to biotic
stimulus (Supplemental Excel file 4, P < 5.03E-38). Remarkably,
a significant proportion of genes whose ileal expression is known
to be regulated by bacterial colonization of mice were contained
within the APOA1 and DUOX2 gene coexpression signatures
(Supplemental Figure 7 and ref. 15). This group included upregulated key drivers of the innate (DUOX2 and DUOXA2) and
adaptive (CXCL9 and CXCL10) immune responses both in iCD
and following bacterial colonization of the mouse ileum. This
finding suggested that the host gene coexpression signal in CD
may be due, in part, to shifts in the ileal microbial community.
We therefore next defined the ileal microbial community within
the patient cohort and tested for association with genes from the
DUOX2 and APOA1 gene coexpression signatures.
We first performed a univariate analysis (LDA Effect Size)
to test for association between ileal microbial composition and
disease state in 240 subjects with CD, 163 non-IBD Ctl, and 56
subjects with UC from the RISK cohort, with no recent exposure
to antibiotics (Supplemental Excel file 15). The output of this univariate analysis is illustrated by a cladogram, which demonstrates
the relationship between the different bacterial taxa and disease
state (Figure 5A). These results are consistent with prior studies
of patients with IBD with established disease (32) and the recently
published ileal, rectal, and fecal microbial community characteri-
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zation of the RISK cohort (6). We observed prominent increased
abundance of the Firmicutes phyla within the non-IBD Ctls that
was preserved in the UC ileum but not in CD ileum, along with
a shift toward Fusobacteria, Gemellaceae, and Proteobacteria expansion in the CD ileum.
Microbial shifts that have previously been defined in the ileal
mucosa of patients with adult-onset CD with longstanding disease could be secondary to adaption to the diseased micro-environment or a primary event independent of local inflammation
(5, 32). To address this fundamental pathogenic question, we next
uniquely characterized the ileal microbial community in patients
with CD without clinical ileal involvement (cCD), compared with
those with overt ileal inflammation (iCD), for taxa previously
shown to be associated with treatment-naive pediatric CD (6). As
shown in Figure 5B, a very similar microbial shift was observed
in the ilea between patients with iCD and cCD, irrespective of
histologic involvement in cCD. This included expansion of Veillonellaceae, Pasteurellaceae, Neisseriaceae, Gemellaceae, and
Fusobacteriaceae and persistent suppression of Lachnospiraceae,
Bifidobacteriaceae, Clostridiales, and Erysipelotrichaceae in all
forms of CD, while expansion of Enterobacteriaceae was not apparent in patients with no histological or clinical inflammation. To
examine the possibility that local nearby cecal inflammation contributed to the microbial shift identified in the ileum, we stratified
patients with cCD based on the presence of macroscopic cecal inflammation reported during colonoscopy (Supplemental Figure 8).
Over all, there was persistent reduction in Lachnospiraceae,
Bifidobacteriaceae, Clostridiales, and Erysipelotrichaceae in all
forms of CD, with expansion of Veillonellaceae, Pasteurellaceae,
Neisseriaceae, Gemellaceae, Fusobacteriaceae, and Enterobacteriaceae independent of cecal involvement. Collectively, these
results defined a core CD microbial shift that occurred, like the
APOA1 and DUOX2 gene coexpression signatures, largely in the
absence of overt clinical inflammation (Figure 5B).
Ileal Firmicutes and Proteobacteria taxa abundance are associated with the APOA1 and DUOX2 gene coexpression signatures
and clinical outcomes. To test for an association between the core
CD host gene coexpression signatures and these specific microbial shifts, we performed multivariate analysis by linear models
(MaAsLin) (5, 6) in a subgroup of patients for whom both RNA-Seq
and microbial community profiling had been performed (195 CD,
50 UC, and 34 non-IBD Ctl). We specifically tested for associations between members of the ileal microbial community and representative genes from the APOA1 (APOA1, CXCL9) and DUOX2
(DUOXA2, MUC4, LCT) gene coexpression signatures, clinical
group (Ctl, UC, CD), endoscopic severity (ileal deep ulcers), and
clinical severity (PCDAI), while controlling for age, gender, BMI,
and risk allele carriage in NOD2, FUT2, and ATG16L1. We were
able to identify 70 significant associations between gene expression and microbial taxa and 34 significant associations between
clinical parameters and microbial taxa (P < 0.05 and q < 0.25,
Supplemental Figure 9 and Supplemental Excel file 16).
We then used a novel biplot approach (Figure 6A, ordination
was rotated by CD group) to visualize the covariation among the
ileal microbial community structure, clinical group, CD clinical
disease severity (PCDAI), and ileal gene expression from MaAsLin.
Sample and microbial feature coordinates were generated as a
jci.org   Volume 124   Number 8   August 2014
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Figure 5. The ileal microbial community in patients with IBD and Ctls. (A) Univariate analysis (LDA Effect Size) was performed to test for association
between ileal microbial composition and disease state in 240 CD (48 cCD, 178 iCD, and 14 CD with no indicated ileal involvement), 163 non-IBD Ctl, and
56 UC subjects from the RISK cohort that had not received antibiotics prior to endoscopy. The cladogram illustrates the output of this univariate analysis
by demonstrating the relationship between the different bacterial taxa and disease state. Colored nodes from the center to the periphery represent
marked phylum (p), class (c), order (o), family (f), genus (g), and species (s) differences detected between groups for Ctls (green), CD (red), and UC (blue).
Only phylum, class, order, and family levels are indicated on the right side of the cladogram. (B) Fold change for each taxon was calculated by dividing
the mean abundance in the cases (cCD [48 patients] or iCD [178 patients]) by that of the Ctls (154 patients) and is shown for microbiota with differential
abundance in CD compared with Ctl by univariate analysis. The cCD group was further subdivided to cCD with abnormal histological features (25 patients)
and cCD with normal histology (18 patients).

standard biplot, with an additional dimension of clinical and gene
expression metadata. The biplot used nonmetric multidimensional scaling (NMDS) to depict the multidimensional relationship
between these parameters in 2 dimensions, with the stress measurement indicating the goodness of fit of the 2-dimensional representation of the data. A stress measurement of ≤0.2 is regarded
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as a good fit; during the development of the biplot, 19 of 20 stress
measurements were ≤0.2, demonstrating that the model was not
overfitted to the data. Points were used to represent samples, labels to represent selected significant microbiota, and labeled arrows to represent clinical and molecular metadata (see Methods
section for more details). In the biplot, when we used specifically
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Figure 6. Covariation of the ileal microbial community structure with ileal gene expression and clinical subgroup and severity. (A) The biplot depicts
covariation of the ileal microbial community structure with clinical group, clinical disease activity (PCDAI), and ileal gene expression using NMDS rotated by
CD and based on significant associations obtained from MaAsLin. Patients with IBD and healthy Ctls are plotted as orange circles (Ctl), green circles (UC),
red circles (cCD), purple circles (iCD-noDU), or purple triangles (iCD-DU). Arrows indicate the direction of covariation for APOA1 or DUOXA2 gene expression and clinical severity (PCDAI). Microbial taxa are labeled with capitalized lettering. The stress measurement tests for the goodness of fit of the biplot
2-dimensional depiction of the multidimensional data, with stress < 0.2 regarded as a good fit. (B) The bar plot graphs show effect sizes (r coefficients) on
the x axes for significant associations between microbial taxa and the indicated ileal gene expression, clinical disease activity (PCDAI), and clinical groups
obtained from MaAsLin, while controlling for age, gender, BMI, antibiotic exposure, and NOD2, FUT2, and ATG16L1 risk allele carriage (P < 0.05, q < 0.25
were considered significant). Representative genes are from the APOA1 (APOA1 and CXCL9) and DUOX2 (DUOXA2, MUC4, and LCT) gene coexpression
signatures. The comprehensive presentation of these data with P values, q values, and taxon abundance can be found in Supplemental Excel file 16.

significant microbial taxa associations from the multivariate analysis starting at the family level, we found that Ctl and most UC
ileal samples clustered together with Bifidobacteriales, Lachnospiraceae, and Ruminococcaceae and with a higher level of APOA1
gene expression. Increasing DUOXA2 expression and increasing
clinical disease activity (PCDAI score) were represented by a vector directed to the right of the biplot in association with covariation
in the ileal microbial community structure. A more central CD subgroup clustered together with Firmicutes Veillonellaceae and Betaproteobacteria Neisseriaceae, whereas the remaining CD samples and a small group of UC samples exhibited covariation with
Gammaproteobacteria Pasteurellaceae, Fusobacteriaceae, and
Gammaproteobacteria Enterobacteriaceae, further illustrating the
dysbiosis of these microbiota in the IBD ileum. Consistent with the
univariate analysis, the cCD samples were distributed across the
entire spectrum of the CD microbial community structure.
We next focused on the significant specific associations that
were detected between ileal gene expression and microbial abundance and between clinical metadata (mucosal ulceration, clinical
disease severity, and clinical group) and microbial abundance, as
shown in Figure 6B and Supplemental Excel file 16. Given our multivariate approach, the r coefficients shown are the effect sizes for a
given microbial taxa, which represent the additional association of
that microbe’s relative abundance with a given gene’s expression
or clinical metadata, accounting for the association of all other microbes measured. Because the absolute abundance of each of the

microbial taxa is relatively low, it would be anticipated that the effect sizes would also be low. DUOXA2 and MUC4 expression was
positively associated with taxa from the Proteobacteria phylum (q
< 0.0159 and q < 0.0026, respectively) and Enterobacteriaceae
family, and MUC4 and CXCL9 expression was positively associated with taxa from the Gammaproteobacteria class Pasteurellaceae family (q < 0.1345 and q < 0.176, respectively) (Figure 6B
and Supplemental Excel file 16). Additionally, CXCL9 expression
showed positive association with taxa from Firmicutes Veillonellaceae (q < 0.115). In contrast, DUOXA2, CXCL9, and MUC4 expression was negatively associated with taxa from the Firmicutes
(q < 0.0156, q < 0.137, and q < 0.0012, respectively) and Bacteroidetes phyla (q < 0.0175, q < 0.143, and q < 0.0025, respectively)
(Figure 6B and Supplemental Excel file 16).
In contrast to prior studies of patients with CD with longstanding disease, the presence of more severe mucosal injury
(deep ulcers) that we have now shown to be highly associated with
specific gene signatures and pathways was not associated with a
significant microbial abundance shift in the multivariate analysis.
However, clinical severity scoring (PCDAI) that showed no significant association with mucosal gene expression signature was specifically and significantly associated with reduction in abundance
of Firmicutes (q < 0.1) and Bacteroidetes (q < 0.1) (Figure 6B) and
increase of Proteobacteria taxa (q < 0.038). In addition, prominent
preservation of several taxa within the Firmicutes phyla, including the Roseburia from the Lachnospiraceae family and Erysipelojci.org   Volume 124   Number 8   August 2014
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Figure 7. Host gene expression and microbial shifts across the spectrum of ileal IBD. Progressive induction of an ileal DUOX2 host gene coexpression signature in association with expansion of Proteobacteria taxa was observed in UC, cCD, and iCD, with the greatest change relative to Ctls detected in iCD-DU
(far right). By comparison, alteration of an ileal APOA1 host gene coexpression signature in association with reduction in Firmicutes taxa was specific to all
forms of CD, whereby the majority of the molecular signature of iCD was present in cCD and hence was largely independent of the degree of local inflammation. This emphasizes the central role of the ileum in the pathogenesis of all forms of CD. Maximal overall alteration of these microbial shifts and host
responses favored oxidative stress and Th1 polarization and was associated with the most severe tissue injury manifested as ileal deep ulcers (far right).

trichaceae family, were observed within the UC ileum (q < 0.0025
and q < 0.14, respectively) (Figure 6B, bottom panel). By comparison, APOA1 and LCT expression was positively associated with
Firmicutes (q < 0.04 and q < 0.12, respectively) and Bacteroidetes
(q < 0.06 and q < 0.053, respectively) taxa, while LCT expression
was also inversely associated with abundance of specific Proteobacteria taxa (q < 0.1, Figure 6B, bottom panel). Collectively
these data demonstrate that microbial shifts, which were detected
even in the unaffected ilea of patients with cCD, were associated
with specific changes in expression of genes from the APOA1 and
DUOX2 gene coexpression signatures and the spectrum of ileal
mucosal inflammation and injury in CD and UC, while reduction
of taxa from the Firmicutes phyla, like the APOA1 signature, was
specific to CD and preserved in the ilea of patients with UC.
Finally, we asked whether these gene expression and microbial data, in combination with clinical data at diagnosis, would
improve a prediction model for SSFR 6 months after diagnosis,
when compared with a model based only on clinical factors and
subsequent treatment exposures. Tables 4 and 5 present the results of a multivariable regression analysis to test the accuracy of
models for 6-month SSFR, which, in an iterative fashion, included
clinical parameters only, clinical and gene expression (DUOX2
and APOA1) parameters, or clinical, gene expression, and microbial (taxa identified by MaAsLin) parameters. As shown in Table
4, the accuracy of each of the 3 models was assessed by the area
under the curve (AUC) for a receiver operator curve analysis, with
the likelihood ratio test used to formally test for a difference in
accuracy between the model based only on clinical parameters
and the model which included clinical, gene expression, and microbial parameters. These data demonstrated that a model that
included clinical, gene expression, and microbial factors was superior to a model that included only clinical factors, with the highest AUC of 0.760 and P = 0.0043 (likelihood ratio test), compared
with the model based on only clinical factors.
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The results of the multivariable regression analysis, which
included clinical, gene expression, and microbial parameters, are
shown in Table 5. Neither age at diagnosis nor clinical disease activity (PCDAI) alone was associated with 6-month SSFR. Among
patients with mild clinical disease activity (PCDAI ≤ 30), the presence of ileal deep ulcers was associated with a higher likelihood
of achieving 6-month SSFR, as evidenced by a higher odds ratio
(OR), which reached statistical significance (P = 0.0029). As expected, the highest OR for achieving 6-month SSFR was associated with anti-TNF therapy. After accounting for clinical and mucosal severity and anti-TNF therapy, variable selection and the
classification and regression tree analysis identified higher APOA1
expression (above the sample 80th percentile) and microbial taxa,
including Lachnospiraceae Blautia and Veillonellaceae Veillonella
abundance as significant prognostic factors. The relative abundance of Blautia and Veillonella interactively affected the odds of
attaining 6-month SSFR: while an increased abundance of Blautia (above the sample 70th percentile) was negatively associated
with the odds of achieving 6-month SSFR, its effect was abrogated
by an increased abundance of Veillonella (above the sample 80th
percentile). Finally, we used 10-fold cross-validation to test the
overall reliability of the model and the potential for overfitting. We
divided the data set into 10 subsets and used each subset as a validation set, while using the remaining 9 as a test set. Cross-validation showed that the clinical outcome prediction model using clinical, genetic, and microbial data performed reliably: the predictive
power measured by the AUC on the validation sets was 0.777 on
average, with SEM = 0.011. These data demonstrated that a model
which includes baseline APOA1 expression and Blautia and Veillonella abundance accurately predicts 6-month clinical outcome.

Discussion

Current evidence suggests that host/microbe interactions have
played a fundamental role in the rise of multifactorial autoim-
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mune diseases across the globe (33–36). Here, we report results
of combined clinical, genetic, and high-throughput mucosal transcriptomic and microbial community profiling at the time of IBD
diagnosis of treatment-naive patients, as part of a large multicentered, North American pediatric IBD inception cohort study. Using
this comprehensive approach, we provide evidence for novel core
microbial shifts and associated host gene expression profiles that
are present at the onset of disease and are largely independent of
overt clinical inflammation. Our results support the existence of
a pathogenic model along the spectrum for ileal IBD (UC, cCD,
iCD), as illustrated in Figure 7. We detected a progressive alteration
of an innate antimicrobial DUOX2 coexpression gene signature in
association with expansion of Proteobacteria taxa across all forms
of IBD (UC, cCD, and iCD), whereby mature enterocyte digestive
functions, including LCT expression, decreased as DUOX2 expression increased. We noted an additional CD-specific alteration, already present in the unaffected ilea of patients with cCD, involving
suppression of an antiinflammatory/antioxidant APOA1 gene coexpression signature, in conjunction with induction of an adaptive
IFNG/CXCL9 Th1 signature and depletion of certain Firmicutes
and Bacteroidetes taxa. Collectively these bacterial shifts and host
responses favor oxidative stress and Th1 polarization and are further amplified in association with more severe mucosal injury, as
seen in the presence of mucosal ulceration (Figure 7, iCD-DU).
Our findings of substantially increased expression of both
DUOXA2 and DUOX2 in IBD suggest a central role for DUOX2
in this setting. Indeed, DUOX2 interacts with the CD risk gene
NOD2 in generating intestinal epithelial cell responses to bacterial products (23), and susceptibility to spontaneous colitis in mice
with deletion of antioxidant glutathione peroxidase function has
been mapped to a locus containing Duox2 (24). Altered lipoprotein composition and associated oxidative stress were previously
noted in pediatric CD (25), and a prior report of the global pattern
of ileal gene expression in longstanding adult-onset CD also noted
profound suppression of APOA1 and APOAC3 gene expression
(19). In fact, clustering analysis of the ileal biopsies in the prior
adult-onset study showed that differentiation between CD and Ctl
samples was driven by downregulated genes involved in organic
acid and lipid metabolic processes and solute/cation transporter
activity. This is quite similar to the results of the clustering analysis performed in the current study using the APOA1 gene coexpression signature and provides further evidence that this is a
central pathogenic pathway in CD. Remarkably, APOA1, APOA4,
and APOC3 reside in close proximity on chromosome 11 and were
all downregulated within the APOA1 gene coexpression signature, suggesting regulation by common transcriptional factors. Indeed, HNF4α and HNF4γ binding has been described within the
APOA1/A4/C3 chromosomal region (Supplemental Figure 10),
and intestinal epithelial cell–specific deletion of Hnf4a leads to
spontaneous intestinal inflammation in mice (37).This substantial
suppression of the antioxidant lipoproteins in CD can hence serve
as a potential target for future therapies, whereby supplementing
the apolipoprotein axis could be beneficial to reverse some of the
CD-specific pathogenesis in the ileum.
The broad shifts in Proteobacteria and Firmicutes we observed
were remarkably similar to those previously reported in the ilea
of adult patients with IBD with longstanding disease (5, 32). This
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finding suggests that, at least in a subset of patients, these microbial shifts may be a stable feature of refractory disease. However,
our study adds significantly to the current existing knowledge,
whereby we specifically show that ileal dysbiosis exists in IBD in
the absence of overt clinical inflammation, potentially implying
that such dysbiosis is not simply the result of the inflammatory
process per se, as was previously suggested (5, 32). Consistent with
this idea and with the understanding that microbial compositions
affect host gene expression and vice versa (38), we observed high
concordance between alteration of genes from both the DUOX2
and APOA1 gene coexpression signatures and ileal gene expression detected in germ-free mice following bacterial colonization
(ref. 15 and Supplemental Figure 7).
We therefore applied a previously established multivariate
approach (MaAsLin) (5, 6) to test for association between clinical metadata and microbial taxa to assess, for the first time,
associations between selected genes from the DUOX2 and
APOA1 signatures and microbial taxa, while controlling for host
ATG16L1, NOD2, and FUT2 genotype. Our analyses showed a
significant association between expression of components of
the APOA1 module and specific Firmicutes and Bacteroidetes
taxa and components of the DUOX2 module and specific Proteobacteria taxa and Firmicutes taxa. Of particular interest was
the association among the abundance of Proteobacteria Pasteurellaceae, Firmicutes Lachnospiraceae, and genes associated
with both the innate (DUOXA2 and MUC4) and adaptive (IFNG/
CXCL9) immune responses.
While the overall r coefficients or effect sizes that they
represent were relatively low for specific gene/microbe associations, the associated P and q values were highly significant.
Each of the effect sizes for a given microbial taxa represented
the additional association of that microbe’s relative abundance
with a given gene’s expression, accounting for the association of
all other microbes measured. Because the absolute abundance
of each of the tested microbial taxa was relatively low, it would
be anticipated that the effect sizes would also be low. However,
we do show that significant separation on the biplot between CD
and healthy (Ctl) and disease (UC) Ctls was achieved by including these more specific taxa, and these genus level taxa were
also shown to improve a model for 6-month remission. Therefore, these results suggest that although the taxa at the genus
and species level show a low ileal abundance and hence low
effect size for association with gene expression, their presence
is more specifically associated with clinical IBD subgroup and
outcome and therefore pathogenesis. Mechanistic animal studies, including mono-association of germ-free mice with specific
microbes, will be required to define the direct strength of association between these microbes and ileal gene expression.
A fundamental goal of the current study was to test whether
knowledge of the ileal gene expression and/or microbial profile at
diagnosis would have utility in patient classification beyond the
current clinical system. In fact, application of a supervised classification approach to the ileal gene signature which distinguished
cCD from UC in a training cohort was able to classify an independent validation cohort with reasonable accuracy. This may guide
future genomic classification systems for colon-only IBD. We were
further able to test for an association between the net host/microbe
jci.org   Volume 124   Number 8   August 2014

3629

Research article

association present at diagnosis and 6-month SSFR. As expected,
the highest odds of achieving 6-month SSFR were associated with
exposure to anti–TNF-α therapy, with only a modest effect of baseline clinical or mucosal severity. After accounting for these clinical
and treatment factors, we found that patients with CD with higher
baseline ileal APOA1 gene expression and increased Veillonella
abundance relative to Blautia were more likely to attain 6-month
SSFR. This finding may have implications for novel therapeutic
approaches targeting the APOA1 gene coexpression signature and
these specific microbes and stratification of early anti–TNF-α therapy to patients least likely to achieve 6-month remission.
Our study has several strengths but also some limitations.
We examined combined host-transcriptomic and microbial profiles within ileal biopsies obtained at the time of diagnosis in a
large multicenter sample of treatment-naive pediatric patients
with IBD. We included both disease and non-IBD Ctls and used
highly sensitive sequencing and novel analytic approaches in the
largest cohort reported to date. We were thereby able to make
several novel observations regarding the core iCD transcriptome and associated microbiota not previously reported, while
avoiding the potential confounding effects of prior therapy, longstanding duration of disease, and bias toward analysis of surgical resection specimens in prior reports (16, 17, 32). However,
while we report several associations between gene coexpression
modules, specific microbiota, and clinical and mucosal severity,
these studies in patients cannot conclusively establish causality.
Future studies will need to test these putative mechanisms in animal models in order to define primary pathways driving mucosal
gene expression and disease penetrance.
In summary, our results have several pathogenic and clinical
implications. Endoscopic appearance of the classic inflammatory process was absent in the ilea of patients with UC and cCD,
while iCD-associated gene expression and microbial community
differences were remarkably preserved within the cCD subgroup.
We defined an ileal gene set primarily from the APOA1 gene coexpression signature that is CD specific and can potentially be used
to differentiate cCD from UC. Gene-expression based classifiers
are currently used in oncology (39) but are not available in the IBD
field. Our suggested tissue-based molecular classifications may
challenge the accepted IBD clinical classification and pave the
way for potential future diagnostic tissue-based genomic and microbial classifications. In agreement with the clinical discordance
between mucosal ulcers and clinical severity (PCDAI), we failed to
identify a common mucosal-based gene signature and microbial
shift for both tissue injury and clinical severity. We were able to
characterize robust gene expression differences associated with
deep ulcers and enriched pathway associations with oxidative
stress and Th1 polarization. These data can serve to direct future
therapy for ileal mucosal healing, which may not be achieved with
current approaches (12). In contrast, we were able to detect an association between depletion of specific Firmicutes and Bacteroidetes taxa and expansion of Proteobacteria and clinical severity,
as measured by the PCDAI. This would suggest that modification
of the ileal microbial community may be required to achieve sustained clinical remission. This concept is supported by our regression model that included baseline ileal APOA1 expression and
specific microbiota, which was more accurate than one based only
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on clinical factors and anti–TNF-α exposure in predicting 6-month
SSFR. Taken together, these data suggest that, in order to have a
more durable effect, future therapeutic approaches for CD will
need to address these specific microbial shifts, oxidative antimicrobial responses, and the profound loss of basal nuclear receptor-dependent homeostatic mechanisms.

Methods

More comprehensive information can be found in the Supplemental
Methods.
The RISK cohort. Ileal biopsy samples and associated clinical
information were obtained from the RISK study, an ongoing, prospective observational IBD inception cohort sponsored by the Crohn’s
and Colitis Foundation of America. 1,656 children and adolescents
younger than 17 years, newly diagnosed with IBD and non-IBD Ctls,
were enrolled at 28 North American pediatric gastroenterology centers between 2008 and 2012. All patients were required to undergo
baseline colonoscopy and confirmation of characteristic chronic
active colitis/ileitis by histology prior to diagnosis and treatment, with
the recording of findings in standardized fashion. Only subjects with
a confirmed persisting diagnosis of CD, UC, or Ctl during an average
of 22 months follow-up to date were included in this analysis, which
included a representative subgroup of age-matched CD (n = 243),
Ctl (n = 43), and disease Ctl UC (n = 73) patients.
Ileal DNA and RNA extraction and RNA-seq. Ileal biopsies were
obtained at the diagnostic colonoscopy and stored in RNALater at
–80°C. Total DNA and RNA were isolated using the Qiagen AllPrep
RNA/DNA Mini Kit. PolyA-RNA selection, fragmentation, cDNA
synthesis, adaptor ligation, and library preparation were performed
using TruSeq RNA Sample Preparation (Illumina). Single-end 50-bp
sequencing was performed using the Illumina HiSeq 2000 in the
CCHMC NIH-supported Digestive Health Center. Reads were aligned
using TopHat (40). The aligned reads were quantified by Avadis NGS
software (version 1.3.0, build 163982, Strand Scientific Intelligence
Inc.) using Hg19 as the reference genome and reads per kilobase per
million mapped reads (RPKM) as an output. The DESeq algorithm
was used for RPKM normalization within Avadis NGS software. Only
12,415 transcripts with RPKM above 5 in 5 different samples were
included in our downstream differential expression analysis.
RNA-seq expression and gene enrichment analysis. Samples were
stratified into specific clinical subgroups, including Ctl, UC, cCD,
iCD, iCD-noDU, and iCD-DU. For some analyses, cCD were further
subdivided into those with and without microscopic inflammation on
ileal biopsies. Differentially expressed genes were determined by the
Audic Claverie method using the Benjamini-Hochberg false discovery
rate correction (FDR correction 0.05) and analyzed for fold change
differences as indicated. Normalized intensity values were used for
unsupervised hierarchical clustering using Euclidean distance metric
and Ward’s linkage rule to test for groups of ileal biopsies with similar
patterns of gene expression. Pearson correlation based on trend and
rate of change was performed for DUOX2 and APOA1 gene expression
as indicated across Ctl, UC, cCD, iCD-noDU, and iCD-DU for correlation coefficients of 0.98<|r|<1. ToppGene (20), ToppCluster (21),
and IPA (Ingenuity Systems) software were used to test for functional
annotation enrichment analyses of upstream regulators, immune cell
types, pathways, phenotype, and biologic functions. Functional annotation enrichment analyses for immune cell–type enrichments were
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characterized using the Immunological Genome Project data series
through ToppGene. Visualization of the network was obtained using
Cytoscape.v3.0.2 (27).
Immunohistochemistry. Immunohistochemistry detection of
APOA1, DUOX2, and a lipid peroxidation marker (4-hydroxy-2-nonenal
[4-HNE]) was performed as previously described (41) using antiAPOA1 (Abcam, Ab75922), anti-DUOX2 (Santa Cruz Biotechnology,
SC-49938), and 4-HNE (Bioss USA Antibodies, bs-6313R). Staining
was examined using an Olympus BX51 light microscope and digitally
recorded at ×40 magnification.
Support Vector Machine classification model to predict UC or cCD
based on ileal gene expression. A Support Vector Machine–supervised
classification algorithm included in Avadis was used to build a classification model for cCD and UC, using the cCD versus UC ileal gene
expression signature (93 genes with fold change of 2.5) in the training
cohorts (cCD1 and UC1). We then tested the accuracy of the model on
the independent validation cohort (26 cCD2 and 28 UC2). We used
the Avadis linear Support Vector Machine algorithm to build our prediction model on the training cohort (cCD1 and UC1) with its default
parameters (maximum number of iteration = 100,000, cost = 100,
ratio = 1, Kernel paraneter1 = 0.1, Kernel paraneter2 = 1, exponent = 2,
sigma = 1). Building the model also included a 10-time cross-validation process using N-fold (N = 3), in which the classes in the input
data are randomly divided into N equal parts; N – 1 parts are used for
training, and the remaining 1 part is used for testing. Thus, each row
is used at least once in training and once in testing, and a Confusion
Matrix is generated. This model was then tested on the independent
validation cohort (cCD2 and UC2).
Microbial community profiling and analysis of associations between
microbial taxa and clinical and molecular metadata. Detailed protocols
used for 16S amplification and sequencing are as previously described
(42). In brief, 16S rRNA gene sequencing of ileal biopsy DNA was performed using the Illumina MiSeq v2 platform, targeting the V4 region of
the SSU rRNA gene (primers: F [GTGCCAGCMGCCGCGGTAA] and
R [GGACTACHVGGGTWTCTAAT]), according to the manufacturer’s
specifications with addition of 5% PhiX, and generating paired-end
reads of 175 bp in length in each direction. The overlapping paired-end
reads were stitched together, size selected, and further processed in a
data curation pipeline implemented in QIIME (Quantitative Insights In
to Microbial Ecology) 1.5.0 as pick_reference_otus.py (43). Taxonomy
was assigned using the GreenGenes predefined taxonomy map of reference sequence operational taxonomic units (OTUs) to taxonomy (44)
(version of May 2013). The resulting OTU tables were checked for mislabeling (45) and contamination (46) and further microbial community analysis and visualizations. A median sequence depth of 10,000
sequences per sample was obtained, and samples with less than 1,000
filtered sequences were excluded from analysis. OTUs were subsequently converted using QIIME to relative bacterial abundance. QIIME
output was then trimmed down to the species level.
Multivariate analysis (http://huttenhower.sph.harvard.edu/galaxy)
was performed as previously described (5, 6). Tests for association
between taxa of the ileal microbial community and specific clinical
and molecular metadata were conducted using MaAsLin. The following metadata were investigated in the analysis: clinical phenotype (Ctl,
UC, CD), endoscopic severity (deep ulcers in ileum), clinical severity
(PCDAI), and ileal gene expression of APOA1, CXCL9, DUOXA2,
LCT, and MUC4. We controlled for age, gender, BMI (as a measure
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of nutritional status), and NOD2, FUT2, and ATG16L1 IBD risk allele
carriage in the analysis. Significant association was considered below
a q value threshold of 0.25.
A biplot based on NMDS was used to visualize the relationship
between the clinical and molecular metadata and the microbial taxa.
The biplot uses points to represent samples, labels to represent selected
significant microbial features, and labeled arrows to represent study
metadata. Sample and microbial feature coordinates are generated as
a standard biplot, with an additional dimension of metadata. Coordinates of metadata (Figure 6A, arrows) are determined by the center/
average of the coordinates of the samples, with that metadata showing
a central tendency of where that metadata is located. Stress is shown
for the full ordination (both axes in Figure 6A) and can be interpreted
as the percentage difference between current ordination and the data
set in higher dimensions (ranging between no differences at 0.0 to
complete difference at 1.0). Axes in Figure 6A represent the higher
dimensional data set in 2 dimensions as approximated by NMDS. The
full list of significant associations supporting the biplot is shown in Supplemental Excel file 16.
Regression analysis for 6-month SSFR. We used multiple logistic
regression to account for the prognostic power of clinical and medication information and assess additional prognostic power resulting from
including gene expression and microbial data in predicting SSFR after
diagnosis. Clinical and medication information included in the models were age at diagnosis, baseline clinical severity defined by PCDAI
(≤30 or >30), baseline mucosal severity defined by ileal deep ulceration
(present or absent), and late anti-TNF therapy treatment (received or
not). We excluded 7 patients with CD who received anti-TNF as initial therapy. Among the remaining 165 patients with CD, 27 received
anti-TNF subsequent to other therapies (late anti-TNF therapy) prior
to month 6. We considered 2 gene expression variables (APOA1 and
DUOX2) and microbial variables that were preidentified by the previous multivariate gene expression and microbiome analyses (Figure 6A
and Supplemental Excel file 16). We then used variable selection and
classification and regression tree analysis to construct 3 logistic regression models that respectively include clinical information only, clinical
and significant gene expression variables, and clinical and significant
gene expression and microbial variables. The reliability of the final
model was tested by 10-fold cross-validation.
Statistics. Differentially expressed genes between groups were
determined by the Audic Claverie method using the Benjamini-Hochberg FDR correction (FDR 0.05) and analyzed for fold change differences as indicated. Differences in expression for specific genes between
patient subgroups were tested using Kruskal-Wallis with Dunn’s multiple comparison test. P < 0.05 was considered significant. ToppGene
(20) and ToppCluster (21) software was used to test for functional annotation enrichment of immune cell types, pathways, phenotype, and
biologic functions with FDR P < 0.05. The Avadis linear Support Vector
Machine–supervised classification algorithm was used with its default
parameters (maximum number of iteration = 100,000, cost = 100,
ratio = 1, Kernel paraneter1 = 0.1, Kernel paraneter2 = 1, exponent = 2,
sigma = 1) to build a classification model for cCD and UC. Building the
model also included a 10-time cross-validation process using N-fold
(N = 3), in which the classes in the input data are randomly divided
into N equal parts; N – 1 parts are used for training, and the remaining
1 part is used for testing. Multivariate analysis (http://huttenhower.
sph.harvard.edu/galaxy) was performed as previously described (5, 6).
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Significant association was considered below a q value threshold of 0.25.
A biplot based on NMDS was used to visualize the relationship between
the clinical and molecular metadata and the microbial taxa. The stress
measurement tests for the goodness of fit of the biplot 2-dimensional
depiction of the multidimensional data, with stress < 0.2 regarded as
a good fit. For 6-month SSFR, we used multiple logistic regression to
account for the prognostic power of clinical and medication information
and assess additional prognostic power resulting from including gene
expression and microbial data in predicting SSFR after diagnosis.
The RNA-seq data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (47) and are accessible with
GEO series accession number GSE57945 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE57945). The microbial data were previously deposited as described (6).
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Angeles, Los Angeles, California, USA; Baylor College of Medicine,
Houston, Texas, USA; Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, USA; Children’s Hospital of Eastern Ontario; Johns
Hopkins Medical Center, Baltimore, Maryland, USA; University of
1. Aujnarain A, Mack DR, Benchimol EI. The role of
the environment in the development of pediatric
inflammatory bowel disease. Curr Gastroenterol
Rep. 2013;15(6):326.
2. Molodecky NA, et al. Increasing incidence and
prevalence of the inflammatory bowel diseases
with time, based on systematic review.
Gastroenterology. 2012;142(1):46–54.e42
3. Kim SC, Tonkonogy SL, Karrasch T, Jobin C, Sartor RB. Dual-association of gnotobiotic IL-10–/–
mice with 2 nonpathogenic commensal bacteria
induces aggressive pancolitis. Inflamm Bowel Dis.
2007;13(12):1457–1466.
4. Jostins L, et al. Host-microbe interactions have
shaped the genetic architecture of inflammatory
bowel disease. Nature. 2012;491(7422):119–124.
5. Morgan XC, et al. Dysfunction of the intestinal
microbiome in inflammatory bowel disease and
treatment. Genome Biol. 2012;13(9):R79.
6. Gevers D, et al. The treatment-naive microbiome
in new-onset Crohn’s disease. Cell Host Microbe.
2014;15(3):382–392.
7. Hotte NS, et al. Patients with inflammatory
bowel disease exhibit dysregulated responses to
microbial DNA. PLoS One. 2012;7(5):e37932.
8. Colombel JF, et al. Infliximab, azathioprine, or
combination therapy for Crohn’s disease.
N Engl J Med. 2010;362(15):1383–1395.
9. Sandborn WJ, et al. Ustekinumab induction and
maintenance therapy in refractory Crohn’s dis-

3632

Texas Southwestern Medical Center, Dallas, Texas, USA; University
of Chicago, Chicago, Illinois, USA; Children’s Hospital at Vanderbilt,
Nashville, Tennessee, USA; Children’s Healthcare of Atlanta, Atlanta,
Georgia, USA; University of North Carolina at Chapel Hill, Chapel
Hill, North Carolina, USA; Boston Children’s Hospital, Boston, Massachusetts, USA; Emory University; Connecticut Children’s Medical
Center; Children’s Hospital of Pittsburgh).

Acknowledgments

This work was supported by the Crohn’s and Colitis Foundation
of America, the Gene and Protein Expression and Bioinformatics
cores of the NIH-supported Cincinnati Children’s Hospital Research Foundation Digestive Health Center (1P30DK078392-01),
the Cincinnati Children’s Hospital Medical Center Innovation
Fund (to L.A. Denson), NIH grant U54DK102557 (to R.J. Xavier,
C. Huttenhower, and D. Gevers), and the Leona M. and Harry B.
Helmsley Charitable Trust. We thank E. Bonkowski, B. Fey, and
R. Steiner for excellent technical work. We thank the Crohn’s
and Colitis Foundation of America RISK study publication committee for critical review of this manuscript. We would also like
to thank the following RISK study investigators: S.B. Snapper, R.
Kellermayer, M. Kappelman, A. Otley, M. Pfefferkorn, S.A. Cohen,
S.L. Guthery, N.S. LeLeiko, M. Oliva-Hemker, D.E. Moulton, B.S.
Kirschner, A.S. Patel, and D.A. Ziring.
Address correspondence to: Lee A. Denson, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati
Children’s Hospital Medical Center, MLC 2010, 3333 Burnet
Avenue, Cincinnati, Ohio 45229, USA. Phone: 513.636.7575;
E-mail: lee.denson@cchmc.org.

ease. N Engl J Med. 2012;367(16):1519–1528.
10. Parikh A, et al. Vedolizumab for the treatment of
active ulcerative colitis: a randomized controlled
phase 2 dose-ranging study. Inflamm Bowel Dis.
2012;18(8):1470–1479.
11. Walters TD, et al. Increased effectiveness of early
therapy with anti-tumor necrosis factor-α vs an
immunomodulator in children with Crohn’s
disease. Gastroenterology. 2014;146(2):383–391.
12. Arijs I, et al. Predictive value of epithelial gene
expression profiles for response to infliximab in Crohn’s disease. Inflamm Bowel Dis.
2010;16(12):2090–2098.
13. Gullberg E, Soderholm JD. Peyer’s patches and
M cells as potential sites of the inflammatory
onset in Crohn’s disease. Ann N Y Acad Sci.
2006;1072:218–232.
14. Jung C, Hugot JP, Barreau F. Peyer’s patches: the
immune sensors of the intestine. Int J Inflam.
2010;2010:823710.
15. Larsson E, et al. Analysis of gut microbial regulation of host gene expression along the length of
the gut and regulation of gut microbial ecology
through MyD88. Gut. 2012;61(8):1124–1131.
16. Zhang T, et al. An ileal Crohn’s disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal
biopsies. PLoS One. 2012;7(5):e37139.
17. Zhang T, et al. Host genes related to paneth cells
and xenobiotic metabolism are associated with

jci.org   Volume 124   Number 8   August 2014

shifts in human ileum-associated microbial composition. PLoS One. 2012;7(6):e30044.
18. Clark PM, Dawany N, Dampier W, Byers SW,
Pestell RG, Tozeren A. Bioinformatics analysis
reveals transcriptome and microRNA signatures
and drug repositioning targets for IBD and
other autoimmune diseases. Inflamm Bowel Dis.
2012;18(12):2315–2333.
19. Noble CL, et al. Characterization of intestinal
gene expression profiles in Crohn’s disease by
genome-wide microarray analysis. Inflamm
Bowel Dis. 2010;16(10):1717–1728.
20. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and
candidate gene prioritization. Nucleic Acids Res.
2009;37(Web Server issue):W305–W311.
21. Kaimal V, Bardes EE, Tabar SC, Jegga AG, Aronow BJ. ToppCluster: a multiple gene list feature
analyzer for comparative enrichment clustering
and network-based dissection of biological systems. Nucleic Acids Res. 2010;
38(Web Server issue):W96–W102.
22. Schwartz S, et al. A metagenomic study of
diet-dependent interaction between gut microbiota and host in infants reveals differences in
immune response. Genome Biol. 2012;13(4):r32.
23. Lipinski S, et al. DUOX2-derived reactive oxygen
species are effectors of NOD2-mediated antibacterial responses. J Cell Sci. 2009;
122(pt 19):3522–3530.

Research article

The Journal of Clinical Investigation  
24. Esworthy RS, Kim BW, Rivas GE, Leto TL,
Doroshow JH, Chu FF. Analysis of candidate
colitis genes in the Gdac1 locus of mice deficient
in glutathione peroxidase-1 and -2. PLoS One.
2012;7(9):e44262.
25. Levy E, et al. Altered lipid profile, lipoprotein
composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr.
2000;71(3):807–815.
26. Allez M, Lemann M, Bonnet J, Cattan P, Jian R,
Modigliani R. Long term outcome of patients
with active Crohn’s disease exhibiting extensive
and deep ulcerations at colonoscopy. Am J
Gastroenterol. 2002;97(4):947–953.
27. Saito R, et al. A travel guide to Cytoscape plugins.
Nat Methods. 2012;9(11):1069–1076.
28. Seeley EH, Washington MK, Caprioli RM,
M’Koma AE. Proteomic patterns of colonic
mucosal tissues delineate Crohn’s colitis and
ulcerative colitis. Proteomics Clin Appl. 2013;
7(7–8):541–549.
29. Schnitzler F, et al. Mucosal healing predicts
long-term outcome of maintenance therapy with
infliximab in Crohn’s disease. Inflamm Bowel Dis.
2009;15(9):1295–1301.
30. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller
W. Interleukin-10-deficient mice develop
chronic enterocolitis. Cell. 1993;75(2):263–274.
31. Taurog JD, et al. The germfree state prevents
development of gut and joint inflammatory

disease in HLA-B27 transgenic rats. J Exp Med.
1994;180(6):2359–2364.
32. Frank DN, St Amand AL, Feldman RA, Boedeker
EC, Harpaz N, Pace NR. Molecular-phylogenetic
characterization of microbial community imbalances in human inflammatory bowel diseases. Proc
Natl Acad Sci U S A. 2007;104(34):13780–13785.
33. Bornigen D, et al. Functional profiling of the gut
microbiome in disease-associated inflammation.
Genome Med. 2013;5(7):65.
34. Chappert P, Bouladoux N, Naik S, Schwartz RH.
Specific gut commensal flora locally alters T
cell tuning to endogenous ligands. Immunity.
2013;38(6):1198–1210.
35. Markle JG, et al. Sex differences in the gut
microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;
339(6123):1084–1088.
36. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol.
2011;12(1):5–9.
37. Darsigny M, et al. Loss of hepatocyte-nuclear-factor-4α affects colonic ion transport and
causes chronic inflammation resembling
inflammatory bowel disease in mice. PLoS One.
2009;4(10):e7609.
38. Winter SE, et al. Host-derived nitrate boosts
growth of E. coli in the inflamed gut. Science.
2013;339(6120):708–711.
39. Alexander EK, et al. Preoperative diagnosis of

benign thyroid nodules with indeterminate
cytology. N Engl J Med. 2012;367(8):705–715.
40. Trapnell C, Salzberg SL. How to map billions
of short reads onto genomes. Nat Biotechnol.
2009;27(5):455–457.
41. Carey R, et al. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset
inflammatory bowel disease. Inflamm Bowel Dis.
2008;14(4):446–457.
42. Caporaso JG, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq
and MiSeq platforms. ISME J. 2012;6(8):1621–
1624.
43. Caporaso JG, et al. QIIME allows analysis of
high-throughput community sequencing data.
Nat Methods. 2010;7(5):335–336.
44. McDonald D, et al. An improved Greengenes
taxonomy with explicit ranks for ecological and
evolutionary analyses of bacteria and archaea.
ISME J. 2012;6(3):610–618.
45. Knights D, et al. Supervised classification of
microbiota mitigates mislabeling errors. ISME J.
2011;5(4):570–573.
46. Knights D, et al. Bayesian community-wide culture-independent microbial source tracking.
Nat Methods. 2011;8(9):761–763.
47. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res.
2002;30(1):207–210.

jci.org   Volume 124   Number 8   August 2014

3633

